Surprise! Pfizer jumps the queue and leaps into RSV vax contention as COVID helps turbo...

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Jul 30, 2021 at 11:12 AM.

  1. cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    32,741
    Likes Received:
    3
    via Watch out, GlaxoSmithKline and Johnson & Johnson, Pfizer is steaming into the respiratory syncytial virus (RSV) vaccine race in what looks like a late break that could soon become gold.

    In data dropped rather quietly during second-quarter earnings this week and to little fanfare, Pfizer said a challenge study, where vaccines were given to 62 adults under 50 who were then intentionally infected with RSV to see if the shot worked, showed “100% observed efficacy against mild to moderate symptomatic infection resulting from RSV.”

    article source